Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Vericel Corp Ord

Healthcare US VCEL

35.85USD
1.11(3.20%)

Last update at 2026-06-04T17:44:00Z

Day Range

35.3836.86
LowHigh

52 Week Range

30.1853.05
LowHigh

Fundamentals

  • Previous Close 34.74
  • Market Cap2344.06M
  • Volume425026
  • P/E Ratio4823.00
  • Dividend Yield-%
  • EBITDA1.10M
  • Revenue TTM207.78M
  • Revenue Per Share TTM4.35
  • Gross Profit TTM 109.79M
  • Diluted EPS TTM0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -15.98800M -7.58200M 3.04M -9.66500M -8.13700M
Minority interest - - - - -
Net income -16.70900M -7.47100M 2.86M -7.90900M -8.13700M
Selling general administrative 106.90M 97.59M 68.84M 61.14M 49.01M
Selling and marketing expenses - - - - -
Gross profit 109.79M 106.03M 84.23M 80.28M 58.70M
Reconciled depreciation 3.98M 2.96M 2.38M 1.74M 1.43M
Ebit -17.05800M -7.85400M 0.67M -11.25100M -4.46900M
Ebitda -15.62200M -7.57800M 3.05M -9.65700M -3.04300M
Depreciation and amortization 1.44M 0.28M 2.38M 1.59M 1.43M
Non operating income net other 1.44M 0.28M 0.69M 1.61M -4.19700M
Operating income -17.05800M -7.85400M 0.67M -11.25100M -3.90900M
Other operating expenses 181.42M 164.04M 121.81M 129.10M 94.77M
Interest expense 0.37M 0.00400M 0.00600M 0.00800M 1.73M
Tax provision 0.72M -0.11100M 0.18M - -
Interest income 1.34M 0.22M 0.69M 1.61M 0.90M
Net interest income 0.97M 0.22M 0.69M 1.61M -0.83500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.72M -0.11100M 0.18M -1.75600M 3.36M
Total revenue 164.37M 156.18M 124.18M 117.85M 90.86M
Total operating expenses 126.85M 113.88M 81.86M 91.53M 62.61M
Cost of revenue 54.58M 50.16M 39.95M 37.57M 32.16M
Total other income expense net 1.07M 0.27M 2.38M 1.59M -3.39300M
Discontinued operations - - - - -
Net income from continuing ops -16.70900M -7.47100M 2.86M -9.66500M -8.13700M
Net income applicable to common shares -16.70900M -7.47100M 2.86M -9.66500M -8.13700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 353.66M 273.00M 243.71M 205.61M 153.24M
Intangible assets 6.88M 7.50M - - -
Earning assets - - - - -
Other current assets 6.85M 4.80M 4.25M 3.89M 2.95M
Total liab 127.70M 80.73M 73.24M 71.35M 42.15M
Total stockholder equity 225.95M 192.27M 170.46M 134.26M 111.09M
Deferred long term liab - - - - -
Other current liab 17.21M 16.23M 0.04M 0.04M 0.04M
Common stock 629.23M 593.25M 553.90M 510.06M 489.75M
Capital stock 629.23M 593.25M 553.90M 510.06M 489.75M
Retained earnings -403.17700M -399.99500M -383.28600M -375.81500M -378.67900M
Other liab - - 0.04M - -
Good will - - - - -
Other assets 0.00000M 1.30M 0.53M 57.92M 0.09M
Cash 86.87M 51.07M 68.33M 33.62M 26.89M
Cash and equivalents - - - - -
Total current liabilities 45.75M 37.46M 26.05M 22.48M 19.80M
Current deferred revenue - - 14.04M 11.29M 7.95M
Net debt 1.28M -3.49700M -18.23300M 19.56M 0.81M
Short term debt 6.19M 4.30M 2.95M 4.39M 5.46M
Short long term debt - - - - -
Short long term debt total 88.14M 47.57M 50.10M 53.18M 27.70M
Other stockholder equity - 592.27M 177.93M 127.61M 0.02M
Property plant equipment - 57.37M 59.03M 57.74M 32.25M
Total current assets 205.63M 186.87M 158.46M 123.56M 111.66M
Long term investments 25.28M 19.96M 25.69M 24.10M 9.25M
Net tangible assets - 184.77M 170.46M 134.26M 111.09M
Short term investments 40.47M 68.47M 35.07M 42.19M 42.83M
Net receivables 58.36M 46.54M 37.44M 34.50M 32.17M
Long term debt - - - - -
Inventory 13.09M 15.99M 13.38M 9.36M 6.82M
Accounts payable 22.35M 16.93M 9.02M 6.75M 6.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10000M -0.97800M -0.15400M 0.01M 0.02M
Additional paid in capital - - - - -
Common stock total equity - 593.25M 553.90M 6.63M 489.75M
Preferred stock total equity - - - - -
Retained earnings total equity - -399.99500M -383.28600M -375.81500M -378.67900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.77M 1.30M 0.53M 0.21M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 148.03M 86.14M 85.24M 82.05M 41.58M
Capital lease obligations 88.04M 47.61M 50.18M 53.30M 27.85M
Long term debt total - - - - 0.11M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -36.20600M 4.41M -14.53400M 13.23M -64.34900M
Change to liabilities 3.58M 4.24M 3.39M -0.07000M 2.43M
Total cashflows from investing activities -36.20600M -3.50100M -17.16000M 10.62M -67.02700M
Net borrowings -1.07600M - - - -18.24200M
Total cash from financing activities 1.04M 9.17M 6.44M 5.26M 58.86M
Change to operating activities -0.93900M -0.68700M -1.53100M -1.66400M 0.02M
Net income -16.70900M -7.47100M 2.86M -9.66500M -8.13700M
Change in cash -17.47400M 34.71M 6.85M 8.69M -8.57600M
Begin period cash flow 68.54M 33.83M 26.98M 18.29M 26.86M
End period cash flow 51.07M 68.54M 33.83M 26.98M 18.29M
Total cash from operating activities 17.69M 29.04M 17.57M -7.18300M -0.41200M
Issuance of capital stock 3.65M 11.18M - 0.00000M 74.39M
Depreciation 3.98M 2.96M 2.38M 1.74M 1.43M
Other cashflows from investing activities - - - 13.23M -64.34900M
Dividends paid - - - - -
Change to inventory -2.60500M -4.02500M -2.54000M -3.25800M 0.23M
Change to account receivables -9.10200M -2.93300M -2.33600M -8.71400M -5.18400M
Sale purchase of stock 3.65M 11.18M 6.63M 5.29M 77.11M
Other cashflows from financing activities -2.60700M -2.01300M 6.44M 5.26M 2.01M
Change to netincome 37.20M 34.33M 13.94M 13.22M 10.66M
Capital expenditures 7.60M 7.92M 2.63M 2.62M 2.68M
Change receivables -9.10200M -2.93300M -2.33600M -8.71400M -5.18400M
Cash flows other operating 1.14M 0.98M -0.44600M 0.17M -1.51400M
Exchange rate changes - - - - -
Cash and cash equivalents changes -17.47400M 34.71M 6.85M 8.69M -8.57600M
Change in working capital -11.20900M -6.15400M -6.37400M -14.66000M -4.03200M
Stock based compensation 37.18M 34.32M 13.84M 13.18M 7.22M
Other non cash items 3.72M 4.43M 4.45M 2.79M 3.11M
Free cash flow 10.09M 21.12M 14.95M -9.79900M -3.09000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VCEL
Vericel Corp Ord		 1.11 3.20% 35.85 4823.00 322.58 11.73 10.26 11.62 801.64
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Corp Ord

64 Sidney Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Mr. Dominick C. Colangelo Esq. CEO, Pres & Director 1964
Mr. Joseph Anthony Mara Jr. CFO & Treasurer 1976
Mr. Michael Halpin Chief Operating Officer 1961
Mr. Sean C. Flynn Sr. VP, Gen. Counsel & Sec. 1974
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B. Chief Medical Officer 1962
Mr. Jonathan Siegal Principal Accounting Officer, VP & Corp. Controller NA
Mr. Eric Burns Exec. Director of Financial Planning and Analysis & Investor Relations NA
Mr. Patrick J. Fowler Sr. VP of Corp. Devel. & Strategy NA
Ms. Heidi Hassen VP of HR NA
Mr. Roland DeAngelis Sr. VP of Commercial Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.